Biomarkers for treatment response in advanced prostate cancer

Samia Asif, Benjamin A. Teply

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Multiple treatment options with different mechanisms of action are currently available for the management of metastatic prostate cancer. However, the optimal use of these therapies— specifically, the sequencing of therapies—is not well defined. In order to obtain the best clinical outcomes, patients need to be treated with the therapies that are most likely to provide benefit and avoid toxic therapies that are unlikely to be effective. Ideally, predictive biomarkers that allow for the selection of the therapies most likely to be of benefit would be employed for each treatment decision. In practice, biomarkers including tumor molecular sequencing, circulating tumor DNA, circulating tumor cell enumeration and androgen receptor characteristics, and tumor cell surface expression (PSMA), all may have a role in therapy selection. In this review, we define the established prognostic and predictive biomarkers for therapy in advanced prostate cancer and explore emerging biomarkers.

Original languageEnglish (US)
Article number5723
Issue number22
StatePublished - Nov 1 2021


  • Biomarkers
  • Predictive
  • Prognostic
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Biomarkers for treatment response in advanced prostate cancer'. Together they form a unique fingerprint.

Cite this